Hryniuk W., Bush
H.The importance of dose intensity in
chemotherapy of metastatic breast cancer . J Clin
Oncol.1984;2:1281-1288.
2.
Hryniuk W., Levine
MNAnalysis of dose intensity for adjuvant
chemotherapy trials in stage II breast cancer. J Clin
Oncol.1986;4:1162-1170.
3.
Frei E., Canellos
GPDose: a critical factor in cancer
chemotherapy. Am J
Med.1980;695:585-594.
4.
Peters WP, Ross M.,
Vredenburgh
JJ, et al.High-dose chemotherapy
and autologous bone marrow support as consolidation after standard-dose adjuvant therapy
for high-risk primary breast cancer. J Clin
Oncol.1993;11:1132-1143.
5.
Bezwoda WR, Seymor L.,
Dansey
RDHigh-dose chemotherapy with hematopoietic
rescue as primary treatment for metastatic breast cancer: a randomized
trial. J Clin
Oncol.1995;13:2483-2489.
6.
Gilbert CJPeripheral blood
progenitor cell transplantation for breast cancer: pharmacoeconomic
considerations.
Pharmacotherapy.1996;16 (3
Pt 2):101S-108S.
7.
Antman KH, Rowlings PA,
Vaughan
WP, et al. High-dose chemotherapy with autologous
hematopoietic stem cell support for breast cancer in North America. (In
press).
